AKQA appoints Jon Holloway as Managing Director for the MENA region
With a global career spanning across the EMEA, APAC, and MENA regions, Holloway brings more than two decades of experience as a creative and strategic leader.
Known for building empowered teams and delivering impactful work, Holloway has consistently led businesses and clients through transformation. His leadership has contributed to award-winning work recognised by Cannes Lions, D&AD, Effies and leading creative festivals worldwide.
Based between the UAE and KSA, Holloway will aim to accelerate the agency's momentum in the region, partnering with ambitious brands to shape new experiences at the intersection of creativity, culture and emerging technology.
Geoff Northcott, CEO of AKQA EMEA, said, 'Holloway brings a compelling blend of entrepreneurial spirit, creative leadership and regional expertise. His vision for harnessing AI and innovation in culturally resonant ways aligns perfectly with our ambitions for the Middle East. We're delighted to welcome him as we continue to grow our offering and expand our impact in MENA and beyond.'
Holloway will collaborate closely with AKQA's global and regional leadership teams to deepen client partnerships, grow local talent, and continue evolving the agency's AI-powered creative model for the region.
AKQA's location in the Kingdom of Saudi Arabia is one of the agency's newest office spaces, providing a dedicated environment where clients and employees can collaborate closely.
As the business continues to grow, Holloway plans to expand the studio's offerings and client base across the region.
Reflecting on his appointment, Holloway said, 'It has been a career long dream to join AKQA. There is a rare energy here, a shared ambition to build something bold, culturally connected, and future-facing. Our KSA and UAE locations are already pushing creative boundaries with global and local clients.'
Holloway is also an entrepreneur at heart, having founded and exited fintech ventures. A lifelong advocate for the power of innovation, Jon brings a unique perspective on emerging technologies, including AI and their ability to drive real-world, human-centered impact across clients and industries.
'I'm looking forward to shaping the next chapter in the region,' he added.
Holloway's appointment signals AKQA's continued investment in the Middle East, solidifying its presence in the region and deepening partnerships with clients.
His people-first leadership approach and passion for emerging and enduring technology will aim to accelerate the creative and commercial impact of AKQA's work.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
13 minutes ago
- Zawya
Minapharm's majority shareholder Triquera raises capital through minority stake investment from Admaius Capital Partners
Cairo, Egypt - Admaius Capital Partners ('Admaius'), an Africa-focused private equity investor, and Triquera B.V. ('Triquera'), the majority shareholder in Minapharm Pharmaceuticals and Chemical Industries S.A.E. ('Minapharm'), a leading biopharmaceutical company in the Middle East and Africa and a global provider of proprietary technologies to leading biopharma players, today announced a strategic partnership following Admaius' investment in Triquera B.V. For over two decades, Minapharm has established a robust biopharmaceutical platform that combines world-class R&D with end-to-end manufacturing capabilities for complex genetically engineered therapeutic recombinant proteins and viral vectors as well as small molecules with advanced galenic formulations, operating across facilities in Cairo and Berlin. Today, Minapharm operates the largest biological drug substance and drug product facilities in the Middle East and Africa. Through its international subsidiaries, Minapharm licenses out proprietary technologies in the fields of monoclonal antibodies, vaccines, and cell and gene therapies. These technologies enable the development and production of advanced biologics that address critical unmet medical needs globally and have been incorporated into FDA-approved products, underscoring their clinical relevance and global impact. Together, Triquera and Admaius will focus on accelerating the development and production of complex genetically engineered therapies, while expanding access to high-quality, affordable recombinant proteins by investing in innovation and scaling distribution to better serve patients across underserved markets in Africa and the Middle East. In parallel, the partnership will pursue strategic acquisitions of global contract development and manufacturing organizations (CDMOs) to support Minapharm's growth in the biotech sector. This partnership reflects a shared commitment to advancing healthcare equity through innovation and aligns closely with Admaius' broader strategy of supporting mission-driven businesses and management teams in high-impact sectors across the African continent. Zilla Capital acted as the sole financial advisor to Triquera B.V. and the existing shareholders. Matouk Bassiouny served as legal counsel to Triquera B.V. and the existing shareholders. Admaius Capital Partners was advised by White and Case LLP as legal counsel and by Arthur D. Little as commercial advisor. Commenting on the investment: Dr. Wafik Bardissi, Chairman and CEO of Minapharm, said: "This partnership reflects the accelerating momentum of Minapharm's growth as we extend our leadership in biotherapeutics, cell and gene therapies, and proprietary platform technologies. With Admaius, we gain not only capital but a strategic partner whose insight, alignment, and ambition match our own. Together, we are advancing regional self-sufficiency and expanding the global reach of our innovations." Marlon Chigwende, Managing Partner of Admaius, said: 'This is a landmark transaction. The founding families have built a unique asset on the African and European continents that combines scale, growth and impact to fight cancer and other awful diseases. We are pleased to be able to partner with Triquera, Dr. Wafik and Dr. Shaheer and will help to internationalize and grow the business further.' Ahmed Rady, Managing Director of Admaius, said: 'At Admaius, we back exceptional management teams—and the team behind Minapharm is as impressive as the science, technology, and capabilities they've built across Cairo and Berlin. This partnership is about scaling a homegrown champion that combines cutting-edge global know-how with end-to-end manufacturing excellence. We're excited to support Minapharm in taking this next big step and look forward to working closely with the management team.' Dr. Shaheer Bardissi, Co-CEO of Minapharm, added: 'This strategic collaboration with Admaius will accelerate and scale Minapharm's vision of translating cutting-edge scientific innovation into affordable therapies, while advancing global scientific frontiers in immunotherapy as well as advanced therapy medicinal products, for the benefit of the broader biopharmaceutical industry.' Contacts For more information, please contact: Minapharm Christina Azmy cazmy@ (+2) (02) 24143170 Admaius Hannah Gilkes Phone number: +44 7515 958912
Zawya
2 days ago
- Zawya
Ambassador GAO Wenqi Visits Chinese-Invested Enterprises in Rwanda
On July 25, Ambassador GAO Wenqi visited the C&D Products Group. The company executives gave a briefing on the company's production, operations, and development, as well as the working and living conditions of its employees. Ambassador GAO encouraged the company to adhere to safe production and compliant operation, and take good care of its employees, so as to actively fulfill its social responsibilities and set up a good image for Chinese enterprises. He also asked the company to actively take part in and contribute to Rwanda's economic and social development, and promote China-Rwanda relations. Specializing in apparel manufacturing and export, C&D was established in Rwanda in 2019. It has created over 7,000 jobs for local communities. Distributed by APO Group on behalf of Embassy of the People's Republic of China in the Republic of Rwanda.
TECHx
3 days ago
- TECHx
Google Unveils AI Tool to Decode Ancient Roman Inscriptions
Home » Emerging technologies » Artificial Intelligence » Google Unveils AI Tool to Decode Ancient Roman Inscriptions Google DeepMind has revealed a new artificial intelligence tool called Aeneas, developed to help historians study ancient Roman inscriptions, The Guardian reported. The tool is designed to analyze and restore Latin texts that are often damaged or incomplete. It identifies the origin and estimated date of the inscriptions and can suggest missing words. According to DeepMind, Aeneas was created in collaboration with historians, including Dr. Thea Sommerschield from the University of Nottingham. The AI was trained on a dataset of nearly 200,000 Latin inscriptions, covering more than 16 million characters. These inscriptions, found on monuments, tombs, and everyday objects, offer key insights into life in ancient Rome. However, many inscriptions are partially destroyed or worn. Aeneas uses linguistic and historical patterns to compare the damaged texts with similar examples from the 7th century BC to the 8th century AD. The tool can determine the Roman province of origin. It estimates the date of the inscription within a 13-year range. DeepMind reported that Aeneas can also propose likely words for missing text segments. It has been tested on inscriptions where the original wording is already known, delivering accurate results. The AI successfully interpreted famous examples like the Res Gestae Divi Augusti and linked similar texts across regions of the Roman Empire. Historians described the tool as 'transformative.' In a trial involving 23 researchers, 90% found Aeneas useful in their analysis.
